IN THIS ISSUE:

Notice - Clarification
Academic Research Enhancement Award ................................................. Page 1
  National Institutes of Health
  Index - NATIONAL INSTITUTES OF HEALTH

Notice
Stipend Increase for NRSA Trainees and Fellowships
  for Fiscal Year 1985 .......................................................... Page 2
  National Institutes of Health
  Index - STIPENDS

Notice
To All Persons Interested in the Management of
 NRSA Training Programs ..................................................... Page 3
  National Institutes of Health
  Index - NATIONAL RESEARCH SERVICE AWARDS

Announcement
Notice of Availability
Small Business Innovation Research Program ............................ Page 4
  National Institutes of Health
  Index - NATIONAL INSTITUTES OF HEALTH

Notice
New Provisions for Late R&D Contract Proposals ....................... Page 5
  National Institutes of Health
  Index - CONTRACTS

Announcement
Research Centers in Minority Institutions Award .......................... Page 7
  National Institutes of Health
  Index - INSTITUTIONAL AWARDS

Continued

The NIH Guide is published at irregular intervals to announce scientific initiatives and to provide policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in grants and contracts activities administered by the National Institutes of Health.

Two types of supplements are published by the respective awarding units. Those printed on yellow paper concern contracts: solicitations of sources and announcement of availability of requests for proposals. Those printed on blue paper concern invitations for grant applications in well-defined scientific areas to accomplish specific program purposes.

Have You Moved?
If you present address differs from that shown on the address label, please send your new address to: Grants and Contract Guide Distribution Center, National Institutes of Health, Room B3BN10, Building 31, Bethesda, Maryland 20205, and attach your address label to your letter. Prompt notice of your change of address will prevent your name from being removed from our mailing list.
Announcement
National Eye Institute
Index - EYE

Announcement
Availability of Request for Applications: RFA NLM-85-01 - Specialized National Reference Center for Bioethics Literature ........................................... Page 12
National Library of Medicine
Index - LIBRARY OF MEDICINE

Announcement
Availability of Request for Applications: RFA 85-AI-02 - Program Projects on the Biology of the Immune System .................................................. Page 14
National Institute of Allergy and Infectious Diseases
Index - ALLERGY AND INFECTIOUS DISEASES

Announcement
Availability of Request for Applications: RFA 85-AI-03 - Centers for Interdisciplinary Research on Immunologic Diseases ........................................ Page 16
National Institute of Allergy and Infectious Diseases
Index - ALLERGY AND INFECTIOUS DISEASES

Announcement
Availability of Request for Applications: RFA 85-AI-04 - Asthma and Allergic Disease Centers and Asthma and Allergic Diseases Centers for Immunodermatologic Studies .............................................. Page 18
National Institute of Allergy and Infectious Diseases
Index - ALLERGY AND INFECTIOUS DISEASES

Announcement
Availability of Request for Applications: RFA 85-DE-01 - Orofacial Pain Research Centers ................. Page 20
National Institute of Dental Research
Index - DENTAL

Announcement
Opportunities for Research in Medical Informatics
Investigator-Initiated Research Grants and New Investigator Research Awards ........................................ Page 22
National Library of Medicine
Index - LIBRARY OF MEDICINE

Continued
Announcement
Research Related to Integrated Academic Information
Management Systems (IAIMS) ........................................ Page 25
National Library of Medicine
Index - LIBRARY OF MEDICINE

Announcement
Human Papilloma Viruses and Genital Warts ..................... Page 28
National Institute of Allergy and Infectious Diseases
Index - ALLERGY AND INFECTIOUS DISEASES

Announcement
Mechanisms of Action of the Drug Cyclosporine .................... Page 30
National Institute of Allergy and Infectious Diseases
Index - ALLERGY AND INFECTIOUS DISEASES

Notice
Keyword Thesaurus ....................................................... Page 32
National Institutes of Health
Index - PUBLICATIONS

Notice
Keyword Thesaurus - Program Types ............................... Page 33
National Institutes of Health
Index - PUBLICATIONS

Notice
Keyword Thesaurus - Keywords ...................................... Page 35
National Institutes of Health
Index - PUBLICATIONS
NOTICE

CLARIFICATION

ACADEMIC RESEARCH ENHANCEMENT AWARD

P.T. 34, 14; K.W. 1200180

NATIONAL INSTITUTES OF HEALTH

In the December 7, 1984 issue of the Guide for Grants and Contracts, the NIH announced a new program of Academic Research Enhancement Awards. This notice, amending the prior eligibility criteria for applicants, has evolved out of discussions with potential applicant institutions, organizations representing them, and other interested parties in the NIH community. We believe that the changes noted below will generate a good response to this unique initiative. We also believe that the changes are fully consonant with the intent of Congress to develop research in those institutions which provide baccalaureate training for a significant number of our Nation's research scientists, but which have historically not been major participants in NIH programs.

Eligibility Criteria: Eligible institutions are those offering baccalaureate degrees in the sciences related to health, that are not eligible for the NIH Biomedical Research Support Grant (BRSG) in Fiscal Year 1985.

Funding decisions will be based on the proposed research project's scientific merit and relevance to NIH programs, and the institution's contribution to the undergraduate preparation of doctoral-level health professionals. Among projects of essentially equivalent scientific merit and program relevance, preference will be given to those submitted by institutions that have granted baccalaureate degrees to 25 or more individuals who, during the period 1977-1984, obtained academic or professional doctoral degrees in the health-related sciences.

1Education institutions eligible for BRSGs include those which received a minimum of three allowable PHS biomedical or health-related behavioral research grants totaling $200,000 (including direct and indirect costs), awarded during FY 1984 (October 1, 1983 through September 30, 1984). Application kits have already been provided to institutions that, according to NIH records, are eligible for BRSG funding in FY 1985. If there is any doubt about eligibility for BRSGs you may contact Office of Grants Inquiries, Westwood Building, National Institutes of Health, Bethesda, Maryland 20205.
NOTICE

STIPEND INCREASE FOR NRSA TRAINEES AND FELLOWS FOR FISCAL YEAR 1985

P.T. 44, 22; K.W. 0720005, 1014002

There will be a stipend increase for all National Research Service Awards (NRSA) for institutional trainees and individual fellows which is effective immediately for all appointments and awards made in Fiscal Year 1985 (October 1, 1984 - September 30, 1985). This increase will be provided on all grants and awards issued by the National Institutes of Health (NIH), Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA), and Health Resources and Services Administration (HRSA)/Division of Nursing. Awards issued for FY 85 prior to the date of this notice will be revised to provide for the new stipend levels. The NIH and the Division of Nursing will implement the stipend increase according to the following guidelines:

1. The increase in stipend allowance is tied to the FY 1985 Budget and therefore should be extended to each trainee or fellow provided for in awards made on or after October 1, 1984. No adjustments will be made retroactively for trainees or fellows either appointed under previous fiscal year institutional NRSA's or included in previous fiscal year individual fellowship awards regardless of whether or not activated. These individuals will receive increased stipend levels associated with their appointments, if any, under FY 1985 awards or beyond.

2. Even though selective prior fiscal year awards may have funds available, those funds may not be used to adjust upward the stipend levels of National Research Service Awardees covered under awards issued prior to FY 1985.

ADAMHA will generally follow these guidelines, but will notify their awardees regarding the specific plans for implementation.

The new stipend levels are as follows:

<table>
<thead>
<tr>
<th>Years of Relevant Experience</th>
<th>New Stipend FY 1985</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>$15,996</td>
</tr>
<tr>
<td>1</td>
<td>17,004</td>
</tr>
<tr>
<td>2</td>
<td>21,996</td>
</tr>
<tr>
<td>3</td>
<td>23,004</td>
</tr>
<tr>
<td>4</td>
<td>24,000</td>
</tr>
<tr>
<td>5</td>
<td>26,004</td>
</tr>
<tr>
<td>6</td>
<td>27,996</td>
</tr>
<tr>
<td>7 or more</td>
<td>30,000</td>
</tr>
<tr>
<td>Predoctoral</td>
<td>6,552</td>
</tr>
</tbody>
</table>

NOTICE

TO ALL PERSONS INTERESTED IN THE MANAGEMENT OF
NRSA TRAINING PROGRAMS

P.T. 44, 22; K.W. 0720005, 1014002

The ten-year period 1970-71 to 1980-81, saw a rise in graduate school tuition of 9.3 percent in private, and 8 percent in public institutions, as derived from a sample of 17 private and 3 public institutions. The cost of graduate school tuition from this same sample of schools rose an average of 14.8 percent in private and 8.7 percent in public institutions in 1982-83. The Consumer Price Index (CPI) from 1982-1983 rose 3.5 percent.

The National Institutes of Health (NIH) has had a long-standing practice of paying the full cost of tuition on training grants. The recent increases in costs, however, are placing a severe strain on the Institutes' ability to sustain both a stable number of trainees and the full payment of tuition.

On July 31, 1984, the Deputy Director for Extramural Research and Training, NIH convened a group of representative Presidents, Vice Presidents, Deans of Graduate Schools, and Training Program Directors from large and small, public and private universities. The participants considered the rising costs of graduate education underlying the increases NIH has seen in tuition requests and made some recommendations as to what might be done to contain NIH expenditures in order to protect the quality of the graduate training programs it supports.

As a result of the recommendations made at that meeting, the NIH is considering adopting a policy in regard to the payment of tuition on training grants similar to that so successfully exercised to help contain personnel costs charged to research grants. The two critical elements of the policy are:

- Tuition on successful new and competing renewal research training awards will be honored at the awarded level for the first year of a multi-year award (generally 5 years). Annual incremental requests would be authorized up to 6 percent per year.

- In the event the amount budgeted is insufficient to meet tuition increases in the outlying years, the institutions will be expected to make up the differences. This may be done in part by reprogramming available funds. NIH Program Managers would be directed to allow the utmost flexibility in reprogramming to protect the number of trainees in the program without jeopardizing the quality of the training experience.

It is planned that this policy would go into effect for all research training awards made from Fiscal Year 1986 funds.
ANNOUNCEMENT

NOTICE OF AVAILABILITY

SMALL BUSINESS INNOVATION RESEARCH PROGRAM

P.T. 34; K.W. 0710035

NATIONAL INSTITUTES OF HEALTH

The Small Business Innovation Research (SBIR) Program, authorized by P.L. 97-219, is intended to stimulate technological innovation within the small business community, provide small businesses with an increased role in Federal research and development, and attract private capital to commercialize the results of Federally funded research. For purposes of the SBIR Program, a "small business" is any concern that is independently owned and operated, is organized for profit, has its principal place of business in the U.S., and has no more than 500 employees.

The National Institutes of Health (NIH), a participant in the SBIR Program, is interested in soliciting proposals for innovative research that will contribute towards meeting its program objectives. In this regard, NIH announces the availability of a solicitation for SBIR contract proposals, to be issued on or around January 15, 1985, with a closing date of April 1, 1985. Requests for the solicitation should be addressed to:

Office of Grants Inquiries
Division of Research Grants
National Institutes of Health
Westwood Building - Room 449
Bethesda, Maryland 20205

Individuals whose names and addresses are already on the NIH SBIR mailing list need not submit a request since a copy of the solicitation will automatically be mailed to them.
NEW PROVISIONS FOR LATE R&D CONTRACT PROPOSALS

P.T. 34; K.W. 1014002

NATIONAL INSTITUTES OF HEALTH

The National Institutes of Health (NIH) research contract solicitations (Requests for Proposals (RFPs) contain specific dates, times and places for receipt of R&D contract proposals. Under the old Federal Procurement Regulations (FPR) NIH was permitted to use an alternate late proposal provision allowing acceptance of late offers if significant cost savings or technical advantages were foreseen.

This is no longer possible under the new Federal Acquisition Regulations (FAR) which replaced the FPR on April 1, 1984. NIH can no longer accept late proposals under any circumstances other than those caused by mishandling in the mail, mishandling at the Government's installation or if only one proposal is received. The text of this new FAR provision follows:

FEDERAL ACQUISITION REGULATION (FAR)
52.215-10 p.52-34

52.215-10 Late Submissions, Modifications, and Withdrawals of Proposals.

As prescribed in 15.407(c)(6), insert the following provision in requests for proposals:

LATE SUBMISSIONS, MODIFICATIONS, AND WITHDRAWALS OF PROPOSALS (APR 1984)

(a) Any proposal received at the office designated in the solicitation after the exact time specified for receipt will not be considered unless it is received before award is made and it—

(1) Was sent by registered or certified mail not later than the fifth calendar day before the date specified for receipt of offers (e.g., an offer submitted in response to a solicitation requiring receipt of offers by the 20th of the month must have been mailed by the 15th);

(2) Was sent by mail (or telegram if authorized) and it is determined by the Government that the late receipt was due solely to mishandling by the Government after receipt at the Government installation; or

(3) Is the only proposal received.

(b) Any modification of a proposal or quotation, except a modification resulting from the Contracting Officer's request for "best and final" offer, is subject to the same conditions as in subparagraphs (a)(1) and (2) above.
(c) A modification resulting from the Contracting Officer's request for "best and final" offer received after the time and date specified in the request will not be considered unless received before award and the late receipt is due solely to mishandling by the Government after receipt at the Government installation.

(d) The only acceptable evidence to establish the date of mailing of a late proposal or modification sent either by registered or certified mail is the U.S. or Canadian Postal Service postmark on the wrapper or on the original receipt from the U.S. or Canadian Postal Service. If neither postmark shows a legible date, the proposal, quotation, or modification shall be processed as if mailed late. "Postmark" means a printed, stamped, or otherwise placed impression (exclusive of a postage meter machine impression) that is readily identifiable without further action as having been supplied and affixed by employees of the U.S. or Canadian Postal Service on the date of mailing. Therefore, offerors or quoters should request the postal clerks to place a hand cancellation bull's-eye postmark on both the receipt and the envelope or wrapper.

(e) The only acceptable evidence to establish the time of receipt at the Government installation is the time/date stamp of that installation on the proposal wrapper or other documentary evidence of receipt maintained by the installation.

(f) Notwithstanding paragraph (a) above, a late modification of an otherwise successful proposal that makes its terms more favorable to the Government will be considered at any time it is received and may be accepted.

(g) Proposals may be withdrawn by written notice or telegram (including mailgram) received at any time before award. Proposals may be withdrawn in person by an offeror or an authorized representative, if the representative's identity is made known and the representative signs a receipt for the proposal before award.

(End of provision)
(R 7-2002.4 1979 MAR)
(1-3.802.1)
ANNOUNCEMENT

RESEARCH CENTERS IN MINORITY INSTITUTIONS AWARD

P.T. 34, 14, 18, FF; K.W. 0780010, 1014001

NATIONAL INSTITUTES OF HEALTH

Application Receipt Date: April 15, 1985

The National Institutes of Health (NIH) is pleased to announce a new type of grant, the Research Centers in Minority Institutions (RCMI) Award. Its purpose is "to establish research centers in those predominantly minority institutions which offer doctoral degrees in the health professions or the sciences related to health...."(Report of the House/Senate Conferees on the Fiscal Year 1985 Appropriation for the Office of the Director, NIH).

The RCMI Program will be managed by the Office of the Director, Division of Research Resources. The program is designed to provide grants of up to $1,000,000 per year, for five years, to help eligible institutions enrich their research environments via selected improvements in their human and physical resources. For example, the funds awarded could be used for the salaries of key research and research-support personnel, instrumentation, and alterations and renovation of facilities. Such expenditures would complement ongoing and planned research activities (e.g., projects funded by Minority Biomedical Research Support grants, Minority Access to Research Career awards, traditional NIH and ADAMHA research project grants, and individual and institutional research fellowships).

To be eligible to compete for an RCMI Award, an institution must have 50 percent or more minority enrollment and offer doctoral degrees in the health professions or the sciences related to health. On the basis of information currently available to the NIH, the following eligible institutions have been notified and have been furnished a copy of the draft guidelines for the RCMI Award:

- Atlanta University Graduate School
- City College of the City University of New York (CUNY)
- Drew Postgraduate Medical School
- Florida A&M School of Pharmacy
- Howard University Graduate School
- Howard University Medical School
- Meharry Medical College
- Morehouse Medical School
- Ponce Medical School, Puerto Rico
- Texas Southern University
- Tuskegee Institute
- University of Puerto Rico, Rio Piedras
- University of Puerto Rico, San Juan
Officials of other doctorate-granting schools who think their institution may be eligible should contact:

Ms. Mary L. Miers  
Institutional Liaison Officer  
Office of Extramural Research and Training  
Shannon Building - Room 115  
National Institutes of Health  
Bethesda, Maryland 20205  
Telephone: (301) 496-5366

The NIH will host a special meeting on January 30, 1985, at which time representatives of the eligible institutions and other interested individuals will have an opportunity to offer comments and recommendations about the draft guidelines. For a copy of the draft guidelines or other information regarding this new program, please contact:

Dr. James F. O'Donnell  
Deputy Director  
Division of Research Resources  
Building 31 - Room 5B03  
National Institutes of Health  
Bethesda, Maryland 20205  
Telephone: (301) 496-6023
NOTICE OF FUTURE AVAILABILITY OF REQUEST FOR APPLICATION: RFA

85-EY-01

CONSTRUCTION, ALTERATION AND RENOVATION, AND INSTRUMENTATION

P.T. 02, 18; K.W. 1002046, 1014001, 0785145, 0785150

NATIONAL EYE INSTITUTE

I. BACKGROUND

The National Eye Institute (NEI) announces the availability of a Request for Applications (RFA) for a program that will support grants in three different areas:

- New Construction
- Alteration and Renovation of Existing Facilities
- Acquisition of Specialized Laboratory Instrumentation

$3,300,000 was appropriated for a Vision Research Facilities Program in Fiscal Year 1985. The following information is being provided to allow the vision research community to begin planning for potential applications. Program guidelines will be finalized following discussion at the January 28, 1985 meeting of the National Advisory Eye Council.

II. MECHANISM OF SUPPORT

A. New Construction is defined as the construction of new buildings, additions to existing facilities, or the completion of "shell" space in new or existing buildings. It is expected that the facilities to be constructed will be utilized by investigators currently supported by the NEI. The NEI will provide between 50-75% of the total allowable cost of the project up to a maximum of $500,000 to $1,000,000. The NEI expects to make no more than 3 awards in this category.

The construction program is described in the Catalog of Federal Domestic Assistance No.13.985, Eye Research Construction Grants. Construction grants made under this program are subject to Executive Order 12372. Awards in support of alteration and renovations or specialized instrumentation are not subject to Executive Order 12372. All awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42USC241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 54.
Eligibility: Any domestic public or non-profit institution, organization, or association is eligible to apply. Applications will be evaluated to determine how the facilities to be constructed expand an existing clinical vision research program judged to be of high scientific merit.

Method of Application: Applicants must use PHS Form 5162-1, (SF424) "Application for Federal Assistance for Construction Programs". Specific Program Guidelines will be available February 1, 1985.

B. Alteration and Renovation and Specialized Instrumentation:

Alteration and renovation support is intended for the costs of modifying existing space and utilities within a finished structure and/or adapting interior building features to the needs of an established vision research program. The NEI may provide up to 75% of the total allowable cost of the project up to a maximum of $200,000. The NEI expects to make no more than 5 awards in this category.

Support may also be provided for specialized laboratory instrumentation. The instrumentation may be project specific, but, ideally may be shared among investigators conducting vision research, and which otherwise might not be justified for individual project grants. The NEI may provide up to 75% of the total purchase price of major laboratory equipment costing in the range of $50,000 to $150,000. The NEI expects to make no more than 8-10 awards in this category.

Eligibility: Any domestic public, profit, or non-profit institution, association, or organization is eligible to apply.

Method of Application: Applicants must use PHS Form 398 "Application for Public Health Service Grant". Specific Program Guidelines will be available February 1, 1985.

III. APPLICATION PROCESS

Specific program guidelines will be available February 1, 1985. The application deadline will likely be in May 1985. Awards will be made in September, 1985.

IV. INQUIRIES

Specific program guidelines (which will be available February 1, 1985) for each of the three areas may be obtained by writing to:

Ms. Tina Abel Williams
National Eye Institute
Building 31 - Room 6A50
Bethesda, Maryland 20205
Additional program information may be obtained from:

Ronald G. Geller, Ph.D.
Associate Director for Extramural and Collaborative Programs
National Eye Institute
Building 31 - Room 6A03A
Bethesda, Maryland 20205

Telephone: (301) 486-4903
ANNOUNCEMENT

AVAILABILITY OF REQUEST FOR APPLICATIONS: RFA

85-LM-01

SPECIALIZED NATIONAL REFERENCE CENTER FOR BIOETHICS LITERATURE

P.T. 16; K.W. 1103002, 0783010, 1004008

NATIONAL LIBRARY OF MEDICINE

Application Receipt Date: April 1, 1985

I. PURPOSE AND OBJECTIVES

Advancing medical science and technology have brought great benefits to society, but in doing so have also brought about numerous moral, legal, and ethical issues. Resolution of bioethical matters frequently depends on access to relevant information, drawn from varied literatures. Indexing of this documentation, sponsored by the National Library of Medicine, is available through BIOETHICSLINE, a computerized bibliographic database. There is also a continuing need for a nationally available, comprehensive collection and repository of the biomedical literature, broadly defined, with access to it mediated by a qualified professional reference staff.

In FY 1985, following competitive selection, the National Library of Medicine intends to support a specialized national reference center for bioethics where appropriate documentation will be collected, organized, and made available for bioethics research.

II. MECHANISM OF SUPPORT

The assistance mechanism will be a specialized center grant. Maximum program resources available for this initiative total $400,000. Future support depends on availability of appropriated funds. Applications for this invitation should be submitted by April 1, 1985. The expected start date for an award is September 1, 1985.

III. REVIEW PROCEDURES AND CRITERIA

Applications will be reviewed by a special panel of non-federal experts. The panel's recommendations will then be considered by the Board of Regents of the National Library of Medicine. Review criteria will include the developmental strategy for acquiring, collecting, and distributing materials, and for publicizing and making them accessible. Since the currently printed Bibliography of Bioethics and NLM's BIOETHICSLINE computerized database are the most widely used databases, the collection and its organizing principles should be compatible with these systems.
Other review criteria include institutional involvement and commitment, collaborative arrangements with outstanding scholarly groups of workers in bioethics and moral philosophy, and a governing structure which assures general direction by bioethicists, health care practitioners, and information specialists. Adequacy of physical space, availability of related library services and materials, and access to online bibliographic database systems will also be considered. Professional qualifications of staff will be carefully scrutinized.

IV. IDENTIFICATION OF CONTACT POINTS

Requests for copies of this RFA may be directed to:

Peter A. Clepper
Biomedical Information Support Branch
Extramural Programs
National Library of Medicine
Bethesda, Maryland 20209

Telephone: 301-496-4221
ANNOUNCEMENT

AVAILABILITY OF REQUEST FOR APPLICATIONS: RFA

85-AI-02

PROGRAM PROJECTS ON THE BIOLOGY OF THE IMMUNE SYSTEM

P.T. 34; K.W. 0705040, 1002004, 1002008, 0710060, 0710065, 0745045

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Application Receipt Date: June 15, 1985

I. BACKGROUND INFORMATION

The Immunobiology and Immunochemistry Branch of the Immunology, Allergic and Immunologic Diseases Program of the National Institute of Allergy and Infectious Diseases (NIAID), supports fundamental studies on the structure and function of the immune system to gain an understanding of immune response mechanisms at their basic cellular and molecular levels as they function in health and disease. Program Projects on the Biology of the Immune System are intended to expand the scope of, and eventually replace, the current Program Projects in Lymphocyte Biology which utilize an integrated multidisciplinary approach for basic biologic studies of immunologically-functional lymphocyte populations. Seven such program projects are currently funded although support for two is scheduled to conclude in 1986. This request for applications (RFA) is intended to encourage the development of applications from collaborating investigators and to coordinate the submission and review of new and renewal program project applications providing equitable opportunity for both to compete for funds currently available for this programmatic activity.

II. RESEARCH GOALS AND SCOPE

The goal of these Program Projects is the attainment of a complete understanding of the structure and function of the immune system and its products, its interaction with other body systems, and full knowledge of the genetic and other factors which regulate its development and function. An ultimate practical application of this information is the use of selected cloned cells of the system or their products for the clinical care or reconstitution of immunodeficient individuals, to alleviate allergic states, to provide resistance to life-threatening infections and to correct aberrant or defective immunoregulatory mechanisms.

The scope of these program projects includes studies of every facet of the immune response, ranging from the initial step of antigen recognition to the final elaboration of immunologically distinctive products of specific immunocytes. Research currently supported by this mechanism was designed to greatly expand knowledge of the morphologic and functional heterogeneity of lymphocyte populations and to develop the capability for identification and selection of lymphocyte subpopulations with specific immune reactivity or antigenic composition, for hybridization of such populations and for selective production of
specific, biologically-active, lymphocyte products. Continuation of such studies is anticipated and appropriate, as are similar studies of macrophages, other accessory and effector cells, and activation, differentiation and regulation of the immune system. Also relevant are investigations on interactions and influences of other body systems with the immune system.

III. MECHANISM OF SUPPORT

Program project grants are awarded to an institution on behalf of a program director for the support of a broadly based, multidisciplinary, long-term research program which has a specific major objective or basic theme. A program project generally involves the organized efforts of groups of investigators who conduct research projects related to the overall program objective. The grant can provide support for the projects and for certain core resources shared by individuals where the sharing facilitates the total research effort. Each component project, supported under a program project grant, is expected to contribute and be directly related to a common theme; the projects should demonstrate an essential element of unity and interdependence.

IV. STAFF CONTACT

A more detailed RFA may be obtained from:

John F. Finerty, Ph.D.
Immunobiology and Immunochemistry Branch, IAIDP
National Institute of Allergy
    and Infectious Diseases
Westwood Building - Room 757
National Institutes of Health
Bethesda, Maryland 20205

Telephone: (301) 496-7551

Prospective applicants are encouraged to submit a one-page letter of intent that includes a brief synopsis of the proposed research and identification of any other participating institutions. The NIAID requests such letters by April 1, 1985, for the purpose of providing an indication of the number and scope of applications to be received. A letter of intent is not binding. It will not enter into the review of any application subsequently submitted and is not a necessary requirement for application. Letters of intent and inquiries should be directed to Dr. Finerty at the address shown above.
ANNOUNCEMENT

AVAILABILITY OF REQUEST FOR APPLICATIONS: RFA

85-A1-04

ASTHMA AND ALLERGIC DISEASE CENTERS AND ASTHMA AND ALLERGIC DISEASES CENTERS FOR IMMUNODERMATOLOGIC STUDIES

P.T. 04; K.W. 00705040, 0715110, 0715120, 0785010, 0710070, 0710030, 0785035

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Application Receipt Date: October 15, 1985

I. BACKGROUND INFORMATION

The Allergy and Clinical Immunology Branch of the Immunology, Allergic and Immunologic Diseases Program of the National Institute of Allergy and Infectious Diseases (NIAID) sponsors fundamental and clinical research concerned with asthma, allergic and immunologic diseases and with relevant mechanisms of hypersensitivity and inflammation. For this purpose, thirteen Asthma and Allergic Disease Centers (AADC) are currently funded; support for five is scheduled to conclude in 1986. This request for applications (RFA) is intended to encourage the criteria and requirements for an AADC and to coordinate the submission and review of new and renewal applications providing equitable opportunity for both to compete for funds currently available for this programmatic activity.

II. RESEARCH GOALS AND SCOPE

The fundamental objective of the NIAID's AADC program is to foster acceleration of the application of knowledge on the immune system emerging from relevant biomedical sciences to clinical hypersensitivity disorders. Especially sought as the requisite factors within a participating institution are quality research in (a) basic science(s), (b) clinical investigation supported by adequate clinical facilities, staff expertise in diagnosis and management of asthmatic and allergic patients, and (c) access to (an) appropriate patient population(s) within a suitable academic/investigative designed to favor multidisciplinary interaction.

The scope of the AADC program represents an effort to foster collaborative approaches that will integrate basic concepts in allergy, immunology, pathophysiology, genetics, microbiology, biochemistry, biostatistics, bioinstrumentation, computer science and pharmacology into clinical investigations, which, in addition to the fields of allergy and clinical immunology, may include such areas as dermatology, rheumatology, infectious diseases, pulmonary medicine, hematology and ototrhinolaryngology, when a high degree of relevance to immunology exits. Program objectives are: to encourage collaboration between basic and clinical scientists; to provide a research environment favorable for such interaction; and to implement clinical application of adequately tested research findings and procedures.
In addition, a feature of the AADC program is the opportunity for Directors to implement educational or community activities. Within the research framework of the Center, a variety of outreach and demonstration projects may be supported.

III. MECHANISM OF SUPPORT

AADC grants are awarded to an institution on behalf of a program director for the support of a broadly based, multidisciplinary, long-term research program which may have a specific objective or basic theme, or may involve the integration of several themes. An AADC generally involves the efforts of groups of investigators who conduct research related to the overall program objective. The grant can provide support for the projects and for certain core resources shared by individuals where the sharing facilitates the total research effort. Each component project supported under an AADC grant is expected to contribute to, and be directly related to, a common theme; the component projects should demonstrate an essential element of unity and interdependence.

IV. STAFF CONTACT

A more detailed RFA may be obtained from:

Dorothy D. Sogn, M.D.
Chief, Allergy and Clinical Immunology Branch
Immunology, Allergic and Immunologic
Diseases Program
National Institute of Allergy
and Infectious Diseases
Westwood Building – Room 752
Bethesda, Maryland 20205

Telephone: (301) 496-8973

Prospective applicants are encouraged to submit a one-page letter of intent that includes a brief synopsis of the proposed research and identification of any other participating institutions. The NIAID requests such letters by July 15, 1985, for the purpose of providing an indication of the number and scope of applications to be received. A letter of intent is not binding. It will not enter into the review of any application subsequently submitted and is not a necessary requirement for application. Letters of intent and inquiries should be directed to Dr. Sogn at the address above.
ANNOUNCEMENT

AVAILABILITY OF REQUEST FOR APPLICATIONS: RFA

85-DE-01

OROFACIAL PAIN RESEARCH CENTERS

P.T. 04; K.W. 0715150, 0785040, 0710100, 0785035, 0785055, 0705055, 0755030, 0414011

NATIONAL INSTITUTE OF DENTAL RESEARCH

Application Receipt Date: June 15, 1985

The National Institute of Dental Research (NIDR) invites applications for one or more multidisciplinary research centers studying orofacial pain. The NIDR is initiating support for centers of research excellence in this area in an effort to accelerate scientific progress related to acute and chronic dental orofacial pain.

The overall purpose of these Centers will be to conduct basic and clinical research expanding knowledge concerning the mechanisms underlying orofacial pain and the etiology, diagnosis, and treatment of various dental and orofacial pain conditions. The ultimate aim of such research is to establish a scientific foundation permitting optimally safe and effective prevention and control of orofacial pain.

In order to be responsive to the intent of this RFA, the proposal for center activity must include both basic and clinical research. It is anticipated that each center will direct some research effort toward studies relevant to chronic orofacial pain.

Research objectives to be addressed in the Orofacial Pain Research Centers may include, but are not limited to the following:

1. Studies to identify and elucidate the biological mechanisms involved in orofacial pain transmission and modulation.

2. Research on CNS mechanisms involved in pathological pain.

3. Neuropharmacological studies of agents for use in the control of chronic orofacial or acute dental pain.

This program is described in the Catalog of Federal Domestic Assistance No. 13.844, Pain Control and Behavioral Studies. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under the PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.
4. Small scale epidemiological studies assisting toward the identification of the incidence and distribution of chronic orofacial pain.

5. Studies of factors influencing human pain perception, as well as studies developing improved behavioral and psychophysiological means of pain assessment.

6. Studies of the basic and clinical aspects of acute dental pain, including postsurgical pain.

7. Basic and clinical studies of chronic pain associated with the temporomandibular joint or myofascial pain, or orofacial pain syndromes such as tic douloureux, atypical facial pain, and postherpetic neuralgia.

8. Experimental or clinical studies that clarify the association between orofacial motor dysfunction and orofacial pain.

9. Studies to develop improved, effective diagnostic and treatment procedures applicable to acute dental pain and to chronic orofacial pain conditions.

The substance of each research program may vary according to local expertise, interest, resources, and recruitment possibilities. Applicants should attempt to develop a unique program which is complementary to, rather than duplicative of, ongoing research. The institution must be willing to make a commitment of resources and staff to ensure the development, operation, and function of the proposed center. Applicants may request up to $300,000 in direct costs for the first year, with appropriate increases in subsequent years. Funding is anticipated for a five year project period with a possibility of renewal.

Copies of the complete RFA and additional information may be obtained from:

Dr. Patricia Bryant
Craniofacial Anomalies, Pain Control, and Behavioral Research Branch
Extramural Programs
National Institute of Dental Research
Westwood Building - Room 506
Bethesda, Maryland 20205

Telephone: (301) 496-7807
ANNOUNCEMENT

OPPORTUNITIES FOR RESEARCH IN MEDICAL INFORMATICS

INVESTIGATOR-INITIATED RESEARCH GRANTS AND NEW INVESTIGATOR RESEARCH AWARDS

P.T. 16, 34; K.W. 1004017, 1004008, 1004015, 0503007

NATIONAL LIBRARY OF MEDICINE

Application Receipt Dates: March 1, July 1, November 1

1. BACKGROUND INFORMATION

Through its extramural programs, the National Library of Medicine (NLM) provides assistance for research into the attributes, organization, and utilization of medical knowledge. For the past five years, in NLM's Medical Informatics program area (formerly called Computers in Medicine) grantees have made notable advances in the health computer and information sciences. Their success has contributed to a growing recognition of this important research field. As a result, it has now become possible for NLM to support additional work in FY 85.

Advances of recent decades in the medical sciences have fostered large changes in traditional patterns of health care, education, and research. These changes emphasize the importance of having accurate, authoritative knowledge conveniently at hand. Furthermore, traditional methods of information retrieval, however widely available, are becoming overwhelmed by new demands and needs. New methods and arrangements for knowledge access must be found. They will depend not only on the evolution of higher technologies but also on better understanding of human mental processes.

NLM's Medical Informatics Research Program represents an attempt to address needs for a wide range of investigations in this area and thereby to foster a new research discipline — Medical Informatics.

This program is described in the Catalog of Federal Domestic Assistance, Medical Library Assistance, 13.879. Grants will be awarded under the authority of the Public Health Service Act, Section 301 (42 USC 241) and administered under PHS grant policies and Federal Regulations, most specifically at 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to review by a Health Systems Agency nor to the requirements of Executive Order 12372.
II. RESEARCH GOALS AND SCOPE

Through this program NLM supports work on fundamental knowledge issues. These concern the extraction, organization, retrieval, and utilization of knowledge, involving methodologies such as artificial intelligence, related computer sciences, computational linguistics, medical decision science, cognitive psychology, and related information-oriented fields. Subjects suitable for support include:

- Better understanding of how health professionals respond to information needs.
- Integration of recorded knowledge into clinical and other scientific activities.
- Optimal organization and retrieval for better teaching and learning of material traditionally stored in libraries.
- Mental processes of medical decision making and problem solving and their replication or simulation by computerized expert systems.
- Reasoning from medical knowledge, including artificial intelligence as applied to knowledge bases and "expert" systems.
- The nature and analysis of medical bibliography.
- The classification, organization, and development of advanced nomenclatures.
- Attributes, formal structures, and retrieval processes for medical languages and sub-languages.
- Representation and organization of knowledge in computerized systems.

These investigations must take place in a health context. NLM must necessarily confine its interests to those aspects of the computer and related sciences which bear on the identification, organization, and retrieval of health information.

III. MECHANISM OF SUPPORT

The assistance mechanisms available are the well-established NIH grants for investigator-initiated research and New Investigator Research Awards. Application forms and instructions for these grants are available at most academic medical centers, or from:

Office of Grants Inquiries  
Division of Research Grants  
National Institutes of Health  
Westwood Building - Room 449  
5333 Westbard Avenue  
Bethesda, Maryland 20205  

Telephone: 301-496-7441
IV. REVIEW PROCEDURES AND CRITERIA

Applications filed on the receipt dates noted above will be referred to an appropriate study section or review committee. The review criteria will be those announced in the instruction forms for the different award mechanisms employed. Applications filed later than the announced dates will be held for the next review cycle.

V. METHOD OF APPLYING

Applications should be submitted on PHS form 398, available from the sources listed above. Applicants should refer to this program announcement in the appropriate block on the application form. The place of application receipt is:

Division of Research Grants
National Institutes of Health
5333 Westbard Avenue
Bethesda, Maryland 20205

Letters of intent are not required or necessary for those interested in support by this program. However, program staff will respond to telephone inquiry or to a brief letter outlining the research envisaged. The staff response will be limited to questions of program scope and relevance. If a proposal, while in the health domain, is outside the scope of this particular program, staff will make every effort to refer the applicant to a more appropriate source of support.

VI. IDENTIFICATION OF CONTACT POINTS

Staff at the National Library of Medicine will assist to the extent possible in matters of scope, relevance, or other questions about review, administration, and funding of applications received in response to this announcement.

Biomedical Information Support Branch
Extramural Programs
National Library of Medicine
Bethesda, Maryland 20209

Telephone: 301-496-4221
ANNOUNCEMENT

RESEARCH RELATED TO INTEGRATED ACADEMIC INFORMATION MANAGEMENT SYSTEMS (IAIMS)

P.T. 16, 34; K.W. 1004017, 0901026, 1004000, 1004005, 1004015, 0410000

NATIONAL LIBRARY OF MEDICINE

Application Receipt Dates: March 1, July 1, November 1

The National Library of Medicine (NLM) invites investigator-initiated research grant applications for studies related to Integrated Academic Information Management Systems (IAIMS). Planning and development of IAIMS at medical centers and other health institutions already have identified a number of unanswered fundamental research questions that go beyond the difficulties of establishing electronic and administrative linking of independent computer systems. Of special importance are questions whose investigations are enhanced by the IAIMS information environment and those questions essential to be answered in order to permit successful implementation of IAIMS prototypes.

I. BACKGROUND

NLM supports research into the role of knowledge in health professional life, new mechanisms and structures for managing this knowledge, and computerized methods for organizing and utilizing knowledge. Such studies may concern principles of information organization or new arrangements for computerized knowledge representation. Also involved may be investigations of artificial intelligence techniques as applied to knowledge bases and expert systems. Other research may involve investigations of how health professionals seek and utilize information for problem-solving, and the managerial and organizational methods for improving information services.

In 1983 NLM initiated an IAIMS planning and development activity as a part of its Medical Library Resource Project Grant Program. The purpose of the IAIMS initiative is to assist health institutions in linking the library systems and the multitude of additional information systems that underpin the complex, modern medical center into an integrated computer-based network. The IAIMS concept was derived from an NLM-sponsored study by the Association of American Medical Colleges (AAMC) to analyze trends in biomedical information transfer and their

This program is described in the Catalog of Federal Domestic Assistance, Medical Library Assistance, 13.879. Grants will be awarded under the authority of the Public Health Service Act, Section 394(b) (42 USC 280b-5) and administered under PHS grant policies and Federal Regulations, most specifically at 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to review by a Health Systems Agency nor to the requirements of Executive Order 12372.
implications for health science libraries over the next decade. The AAMC report, as well as other publications, indicate that effective transfer and utilization of recorded knowledge will require interactive network capabilities within medical centers. NLM provides support for: 1) institution-wide IAIMS planning and policy analysis, 2) IAIMS model development involving some segment or cross-section of the institution-wide strategic plan, and 3) implementation of detailed plans for a full-scale IAIMS prototype. The NLM IAIMS program is described in an earlier NIH Program Announcement (see NIH Guide for Grants and Contracts, Vol. 13, No. 8, June 29, 1984).

II. OBJECTIVES

NLM encourages innovative research to support the development and implementation of IAIMS. In order to be fully effective in transforming information-seeking and utilization behavior, IAIMS must employ state-of-the-art computer and communication technologies, provide relevant information and decision support mechanisms, integrate information and data of different formats and structures, respond to specific information needs and requirements, and provide synthesizing mechanisms to create knowledge bases. IAIMS development provides an expedient opportunity to exploit advances resulting from medical informatics research, as well as a locus for a multitude of studies to improve information access and use in health science research, education, and practice.

Research may address technological aspects of computer and communication systems applications to large-scale networking and information/data file integration, including linguistic and human factors aspects of such applications. Investigations may define specific information needs and representations for various medical center personnel, and devise organizing structures and presentation systems. Studies may also explore synthesizing methods and systems, information filtering techniques, knowledge base and expert systems applications to IAIMS, including artificial intelligence methodologies. Additionally, research may be directed to fundamental scientific questions underlying questions of policy, structures, and processes for managing and delivering information, and the related issues of the economics, ownership, privacy, and protection of information.

III. MECHANISM OF SUPPORT

Applicants will be supported through the customary National Institutes of Health Research Project Grant, in accordance with all PHS policies. Responsibility for the planning, direction, and execution of the proposed research will be solely that of the applicant. The total project period is not expected to exceed three years.

NLM necessarily distinguishes between research related to IAIMS, and IAIMS planning and development projects. Proposed research projects must closely relate to an existing institutional IAIMS project.
IV. ADDITIONAL INFORMATION AND CONTACT POINT

Applications should be prepared on PHS form 398, available at most academic medical centers or from:

Office of Grants Inquiries
Division of Research Grants
National Institutes of Health
Westwood Building - Room 449
5333 Westbard Avenue
Bethesda, Maryland 20205

Telephone: 301-496-7441

Applicants should refer to this program announcement in the appropriate block on the application form.

Letters of intent are not required or necessary for those interested in support by this program. However, program staff will respond to telephone inquiry, or to a brief letter outlining the research envisaged. The staff response will be limited to questions of program scope and relevance. If a proposal, while in the health domain, is outside the scope of this particular program, staff will make every effort to refer the applicant to a more appropriate source of support.

Staff at the National Library of Medicine will assist, to the extent possible, in matters of scope, relevance, or other questions about review, administration, and funding of applications received in response to this announcement.

Biomedical Information Support Branch
Extramural Programs
National Library of Medicine
Bethesda, Maryland 20209

Telephone: 301-496-4221
ANNOUNCEMENT

HUMAN PAPILLOMA VIRUSES AND GENITAL WARTS

P.T. 34; K.W. 0714125, 1002047, 0715220, 1002008

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Application Receipt Dates: March 1, July 1, November 1

The National Institute of Allergy and Infectious Diseases (NIAID) invites applications for regular research grants on the biology and molecular virology of human papilloma viruses (HPV) in association with the pathogenesis, epidemiology and natural history of human warts and laryngeal papillomas.

Genital papillomas (condyloma acuminatum) are now regarded as sexually transmitted and a serious public health problem. During the past five years the number of reported cases of genital papillomas has increased at an alarming rate relative to other sexually transmitted diseases. Most human papillomas are benign and self-limiting, but in some cases they are acute, chronic, persistent or progressive. Under any circumstances genital warts are a concern to the health of the individual and the public. The presence of the viruses in the gravid female genital tract at term introduces a risk of transmission to the newborn. The HPV that infect the genitalia also cause laryngeal papillomas. All age groups appear to be susceptible.

Several strains of HPV obtained from clinical specimens have been concentrated and characterized by restriction endonuclease analysis. Newer molecular technologies led to the cloning of the genome of some HPV strains. In turn, cloned fragments of the genome have been used to make molecular probes for detecting evidence of the HPV in human tissues when no viral particles could be seen or isolated. With these technics HPV strains 6 and 11 have been identified in many cases of condyloma acuminatum and laryngeal warts, but other strains are also be associated with these papillomas. A major obstacle to the study of the biology of HPV and the epidemiology and natural history of human warts has been the lack of adequate means of propagating the viruses. The papilloma viruses appear to be highly species specific. Animal model systems have provided valuable information on the structure and composition of the viruses and some information on pathogenesis. However, there is a dearth of information on replication strategies, viral proteins, immune responses, latency, host factors regulating replication, viral attachment, tissue tropism, modes of natural transmission and epidemiology of the nonmalignant diseases. It is in these areas that NIAID is encouraging new investigations.

This program is described in the Catalog of Federal Domestic Assistance No. 13.856, Microbiology and Infectious Diseases Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 73-410, as amended; 42USC241) and administered under PHS grant policies and Federal Regulations 42CFR Part 52. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.
APPLICATION SUBMISSION AND REVIEW

Eligibility: Universities, medical colleges, hospitals, and laboratories of other public, private or for profit institutions are eligible.

Submission: To identify responses to this announcement, check "yes" and put "Human Papilloma Viruses and Genital Warts," under Item 2 on page 1 of the grant application. Use the regular research grant application form PHS 398 that is available in business offices of most research institutions or from the Division of Research Grants (DRG), NIH.

The completed application should be mailed to:

Division of Research Grants
National Institutes of Health
Westwood Building - Room 240
Bethesda, Maryland 20205

The DRG will assign applications for technical review according to the NIH process for regular grant applications. Assignments for funding decisions will follow programmatic guidelines established for NIH. The earliest possible award date is approximately nine months after the receipt date. The number of awards made will depend on the recommendations of the technical review committee and the availability of funds.

INQUIRIES

Additional information may be obtained from:

William P. Allen, Ph.D.
Westwood Building - Room 736
National Institutes of Health
Bethesda, Maryland 20205

Telephone: (301) 496-7453
ANNOUNCEMENT

MECHANISMS OF ACTION OF THE DRUG CYCLOSPORINE

P.T. 34; K.W. 0710100, 0745040, 0710070, 1002008

GENETICS AND TRANSPLANTATION BIOLOGY BRANCH
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Application Receipt Dates: November 1, March 1, July 1.

The National Institute of Allergy and Infectious Diseases (NIAID) invites investigator initiated research grant applications that will increase our knowledge and understanding of the mechanism of action of the immunosuppressive drug cyclosporine and of its side effects.

Cyclosporine A (CsA) has been used for several years to suppress allograft rejection in patients receiving organ transplants. The use of cyclosporine is reported to be of major importance in improving the survival of kidney, liver and heart transplants. However, it is also recognized that there are serious postoperative problems with toxicity episodes, especially involving the kidney, with growing evidence for the induction of chronic renal injury by cyclosporine. The exact mechanism of action of cyclosporine is unknown. However, the T helper cell appears to be a primary target of CsA action. Controversial claims suggest that CsA affects T or B lymphocytes or both. Long term effects of cyclosporine with respect to repeated infections and/or cancer have not been fully elucidated.

The Genetics and Transplantation Biology Branch wishes to stimulate interest in basic research in molecular biology and immunology to explore the nature of cell surfaces, receptor sites, and T and B cell interactions that might be involved in the mode of action of the drug and induction of unresponsiveness to foreign allograft. Further, studies to define possible pathogenic mechanisms and long term drug effects are encouraged.

Applications in response to this announcement will be assigned and reviewed in accordance with the usual National Institutes of Health (NIH) peer review procedures. They will first be reviewed for scientific and technical merit by a group composed mostly of non-Federal scientific consultants. Following this initial review, applications assigned to NIAID will be evaluated for program relevance by the National Advisory Allergy and Infectious Diseases Council. Applications assigned to other Institutes will be reviewed by the appropriate Councils. The review criteria customarily employed by the NIH for regular research grant applications will prevail.

This program is described in the Catalog of Federal Domestic Assistance No. 13.855, Immunology, Allergic and Immunologic Diseases Research. Awards will be made under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant policies and Federal Regulation 42 CFR Part 74. This program is not subject to intergovernmental review requirements of Executive Order 12372 or Health Systems Agency Review.
All PHS and NIH grant policies governing regular research project grants, including cost sharing, apply to applications received in response to this program announcement.

DEADLINE:

Applications will be accepted in accordance with the usual NIH receipt dates for new applications. Deadline dates are: November 1, March 1, and July 1.

METHOD OF APPLYING

Applications should be submitted on form PHS 398, which is available in the grants and contracts business office at most academic and research institutions or from the Division of Research Grants (DRG, NIH). In space #2 on the first page of this form, indicate the title of this program announcement. The original and six copies of the application should be submitted to:

Application Receipt Office  
National Institutes of Health  
Westwood Building – Room 240  
Bethesda, Maryland 20205

For further information contact:

Justina Grauman, M.S.  
Program Officer  
Genetics and Transplantation Biology Branch  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
Westwood Building – Room 754  
Bethesda, Maryland 20205

Telephone: (301) 496-5598
NOTICE

KEYWORD THESAURUS

During the period February-December of 1984, announcements in the NIH Guide for Grants and Contracts were coded using the Keyword Thesaurus, a project funded by the National Science Foundation and the National Endowment for the Humanities. The purpose of using the codes and terms of the Keyword Thesaurus is to facilitate distribution of announcements and Requests for Applications (RFAs) to faculty and staff members who have interests in the specific areas listed.

Beginning with the current issue (January 1985) the announcements and RFAs will be coded using the new edition of the Keyword Thesaurus (Revised October 1984). For more information about coverage of sponsoring agencies and aims of the Keyword Thesaurus, you may write to:

Mr. John A. Rodman  
Office of Sponsored Projects  
University of Texas at Dallas  
P.O. Box 830688  
Richardson, Texas 75083-0688

For those who may not have obtained a copy of the 1984 Keyword Thesaurus, the relevant portion is excerpted in this issue. In the next issue of the Guide the same list of terms will be indexed in numerical order, by the 7-digit code. As displayed in individual announcements, the initials "P.T." denote "program" and "K.W." identifies one or more keywords corresponding to the subject matter of the program or of the announcement. Occasionally, other keyword terms from the complete Thesaurus maybe used to classify announcements, and codes for Target Groups may be used. For any questions about the NIH use of the Keyword Thesaurus please call Dr. John C. James at 301-496-7554.
## NOTICE

**PROGRAM TYPES**

<table>
<thead>
<tr>
<th>Code</th>
<th>Program Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>Analytical Services</td>
</tr>
<tr>
<td>02</td>
<td>Capital Construction</td>
</tr>
<tr>
<td>04</td>
<td>Centers: Research/Demonstration/Service</td>
</tr>
<tr>
<td>05</td>
<td>Challenge/Fund Raising</td>
</tr>
<tr>
<td>06</td>
<td>Consulting/Visiting Personnel</td>
</tr>
<tr>
<td>08</td>
<td>Cultural Outreach</td>
</tr>
<tr>
<td>12</td>
<td>Demonstration</td>
</tr>
<tr>
<td>14</td>
<td>Development (Institutional/Departmental)</td>
</tr>
<tr>
<td>16</td>
<td>Dissemination of Information</td>
</tr>
<tr>
<td>18</td>
<td>Equipment/Instrumentation</td>
</tr>
<tr>
<td>20</td>
<td>Exhibitions, Collections, Performances</td>
</tr>
<tr>
<td>22</td>
<td>Fellowships</td>
</tr>
<tr>
<td>23</td>
<td>Financial Aid (Scholarships and Loans)</td>
</tr>
<tr>
<td>24</td>
<td>General Operating Support</td>
</tr>
<tr>
<td>25</td>
<td>Instruction/Curriculum Development</td>
</tr>
<tr>
<td>26</td>
<td>International Exchange Programs</td>
</tr>
<tr>
<td>28</td>
<td>Materials Acquisition (Books, Tapes, Etc.)</td>
</tr>
<tr>
<td>30</td>
<td>Preservation/Restoration</td>
</tr>
<tr>
<td>32</td>
<td>Publication</td>
</tr>
<tr>
<td>34</td>
<td>Research</td>
</tr>
<tr>
<td>36</td>
<td>Resources (Shared/Non-Acquisition)</td>
</tr>
<tr>
<td>38</td>
<td>Service Delivery Programs</td>
</tr>
</tbody>
</table>
40  STUDENT SUPPORT (INCLUDING DISSERTATION SUPPORT)

42  SYMPOSIA, CONFERENCES, WORKSHOPS, INSTITUTES, SEMINARS, COLLOQUIA

44  TRAINING/TRAINEE/APPRENTICESHIP/INTERNSHIP

46  TRANSLATIONS/EDITING

48  TRAVEL
**NOTICE**

**KEYWORD THESAURUS - KEYWORDS**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0700000</td>
<td>HEALTH AND SAFETY/MEDICAL SCIENCES/BIOMEDICAL</td>
<td>1003019</td>
<td>Catalysis</td>
</tr>
<tr>
<td>0705000</td>
<td>ANATOMICAL SYSTEMS/SITES</td>
<td>1003003</td>
<td>Chemical Dynamics</td>
</tr>
<tr>
<td>0705005</td>
<td>Bone Marrow</td>
<td>1013020</td>
<td>Chemical Physics</td>
</tr>
<tr>
<td>0705010</td>
<td>Brain</td>
<td>1003006</td>
<td>Chemical Synthesis</td>
</tr>
<tr>
<td>0705015</td>
<td>Cardiovascular System</td>
<td>1003008</td>
<td>Chemistry, Analytical</td>
</tr>
<tr>
<td>0705020</td>
<td>Connective Tissue</td>
<td>0710040</td>
<td>Chemistry, Clinical</td>
</tr>
<tr>
<td>0705025</td>
<td>Digestive System</td>
<td>1003012</td>
<td>Chemistry, Organic</td>
</tr>
<tr>
<td>0705030</td>
<td>Endocrine System</td>
<td>1003014</td>
<td>Chemistry, Physical</td>
</tr>
<tr>
<td>0705035</td>
<td>Fetus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0705040</td>
<td>Immune System</td>
<td>0414004</td>
<td>Clinical Psychology</td>
</tr>
<tr>
<td>0705045</td>
<td>Lymphatic System</td>
<td>1004000</td>
<td>Computer Science</td>
</tr>
<tr>
<td>0705050</td>
<td>Musculoskeletal System</td>
<td>1002015</td>
<td>Cytology</td>
</tr>
<tr>
<td>0705055</td>
<td>Nervous System</td>
<td>0413001</td>
<td>Demography</td>
</tr>
<tr>
<td>0705060</td>
<td>Placenta</td>
<td>0414006</td>
<td>Developmental Psychology</td>
</tr>
<tr>
<td>0705065</td>
<td>Respiratory System</td>
<td>1002052</td>
<td>Development, Animal</td>
</tr>
<tr>
<td>0705070</td>
<td>Sensory System</td>
<td>1002053</td>
<td>Development, Human</td>
</tr>
<tr>
<td>0705075</td>
<td>Urogenital System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0706000</td>
<td>BIOMEDICAL ENGINEERING</td>
<td>0414007</td>
<td>Educational Psychology</td>
</tr>
<tr>
<td>0735005</td>
<td>Automated Clinical Analysis</td>
<td>0500000</td>
<td>Education</td>
</tr>
<tr>
<td>0706010</td>
<td>Bioelectric Phenomena</td>
<td>0710050</td>
<td>Electrophysiology</td>
</tr>
<tr>
<td>0706020</td>
<td>Clinical Engineering</td>
<td>1002017</td>
<td>Embryology</td>
</tr>
<tr>
<td>0706030</td>
<td>Medical/Diagnostic Imaging</td>
<td>0710055</td>
<td>Enzymology</td>
</tr>
<tr>
<td>0706040</td>
<td>Physiological Controls and Systems</td>
<td>1002019</td>
<td>Genetics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1002021</td>
<td>Histology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0710060</td>
<td>Immunoochemistry</td>
</tr>
<tr>
<td>0710000</td>
<td>DISCIPLINES/FIELDS</td>
<td>0710065</td>
<td>Immunogenetics</td>
</tr>
<tr>
<td>0710005</td>
<td>Adolescent Health</td>
<td>0710070</td>
<td>Immunology</td>
</tr>
<tr>
<td>0710010</td>
<td>Aging/Gerontology</td>
<td>0710075</td>
<td>Immunopathology</td>
</tr>
<tr>
<td>1002001</td>
<td>Anatomy</td>
<td>1004017</td>
<td>Information, Science/Systems</td>
</tr>
<tr>
<td>0201013</td>
<td>Animal Diseases/Pathology</td>
<td>0410000</td>
<td>Linguistics/Philology</td>
</tr>
<tr>
<td>0201016</td>
<td>Animal Genetics/Breeding</td>
<td>0901026</td>
<td>Management Sciences</td>
</tr>
<tr>
<td>0201018</td>
<td>Animal Physiology/Morphology</td>
<td>0710080</td>
<td>Medicinal Chemistry</td>
</tr>
<tr>
<td>0401001</td>
<td>Anthropology, Cultural/Social</td>
<td>0607010</td>
<td>Microelectronics</td>
</tr>
<tr>
<td>1004015</td>
<td>Artificial Intelligence</td>
<td>1002027</td>
<td>Microbiology</td>
</tr>
<tr>
<td>1002003</td>
<td>Bacteriology</td>
<td>0413003</td>
<td>Migration</td>
</tr>
<tr>
<td>0404000</td>
<td>Behavioral/Social Studies</td>
<td>1002058</td>
<td>Molecular Genetics</td>
</tr>
<tr>
<td>0414015</td>
<td>Behaviorism/Experimental Psychology</td>
<td>1002028</td>
<td>Mutagens</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1002029</td>
<td>Mycology</td>
</tr>
<tr>
<td>1003002</td>
<td>Biochemistry</td>
<td>0710085</td>
<td>Neurophysiology</td>
</tr>
<tr>
<td>1003015</td>
<td>Biochemistry, Carbohydrates</td>
<td>1002030</td>
<td>Neuroscience</td>
</tr>
<tr>
<td>1003016</td>
<td>Biochemistry, Lipids</td>
<td>0710090</td>
<td>Nuclear Medicine</td>
</tr>
<tr>
<td>1003017</td>
<td>Biochemistry, Nucleic Acid</td>
<td>0710095</td>
<td>Nutrition/Dietetics</td>
</tr>
<tr>
<td>1003018</td>
<td>Biochemistry, Proteins</td>
<td>1013017</td>
<td>Optics</td>
</tr>
<tr>
<td>0710015</td>
<td>Bioengineering</td>
<td>1002032</td>
<td>Parasitology</td>
</tr>
<tr>
<td>1002000</td>
<td>Biological Sciences</td>
<td>0710100</td>
<td>Pharmacology</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------</td>
<td>--------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>1002004</td>
<td>Biology, Cellular</td>
<td>0710130</td>
<td>Pharmacy</td>
</tr>
<tr>
<td>1002006</td>
<td>Biology, Developmental</td>
<td>0414011</td>
<td>Physiological Psychology</td>
</tr>
<tr>
<td>1002008</td>
<td>Biology, Molecular</td>
<td>1002040</td>
<td>Plant Sciences</td>
</tr>
<tr>
<td>1002009</td>
<td>Biology, Radiation</td>
<td>1002041</td>
<td>Plant Virology</td>
</tr>
<tr>
<td>0710020</td>
<td>Biomechanics</td>
<td>1009013</td>
<td>Polymer Science</td>
</tr>
<tr>
<td>0710030</td>
<td>Biomedical Research, Multidisciplinary</td>
<td>0413004</td>
<td>Population Biology</td>
</tr>
<tr>
<td>1002012</td>
<td>Biometry</td>
<td>0414012</td>
<td>Psychobiology</td>
</tr>
<tr>
<td>1013004</td>
<td>Biophysics</td>
<td>0414020</td>
<td>Psychodynamics</td>
</tr>
<tr>
<td>0710035</td>
<td>Biotechnology</td>
<td>0414000</td>
<td>Psychology</td>
</tr>
<tr>
<td>1002013</td>
<td>Botany</td>
<td>0710105</td>
<td>Psychopathology</td>
</tr>
<tr>
<td>0710115</td>
<td>Reproductive Physiology</td>
<td>1013026</td>
<td>Radiation Physics</td>
</tr>
<tr>
<td>0414014</td>
<td>Social Psychology</td>
<td>0715185</td>
<td>Skin Diseases</td>
</tr>
<tr>
<td>0417000</td>
<td>Sociology</td>
<td>0404019</td>
<td>Smoking Behavior</td>
</tr>
<tr>
<td>0710120</td>
<td>Speech Pathology</td>
<td>0715190</td>
<td>Stillbirth</td>
</tr>
<tr>
<td>1010013</td>
<td>Statistics</td>
<td>0715195</td>
<td>Stress</td>
</tr>
<tr>
<td>1003022</td>
<td>Surface Chemistry</td>
<td>0715200</td>
<td>Stroke</td>
</tr>
<tr>
<td>1007009</td>
<td>Toxicology</td>
<td>0715205</td>
<td>Sudden Infant Death Syndrome</td>
</tr>
<tr>
<td>0710125</td>
<td>Transplantation Immunology</td>
<td>0404020</td>
<td>Suicide</td>
</tr>
<tr>
<td>1002045</td>
<td>Viral Studies (Virology)</td>
<td>0715210</td>
<td>Trauma</td>
</tr>
<tr>
<td>1002047</td>
<td>Zoology</td>
<td>0715215</td>
<td>Tumor Immunology</td>
</tr>
<tr>
<td>0715000</td>
<td>DISEASE ENTITIES/MEDICAL PROBLEMS, BEHAVIOR AND FACTORS AFFECTING HEALTH</td>
<td>0715220</td>
<td>Venereal Diseases</td>
</tr>
<tr>
<td>0715005</td>
<td>Accidents</td>
<td>0404009</td>
<td>Violent Behavior</td>
</tr>
<tr>
<td>0404001</td>
<td>Addiction</td>
<td>0720000</td>
<td>EDUCATION/INSTRUCTION</td>
</tr>
<tr>
<td>0404003</td>
<td>Alcohol/Alcoholism</td>
<td>0502002</td>
<td>Alcohol Education</td>
</tr>
<tr>
<td>0715010</td>
<td>Arthritis</td>
<td>0720005</td>
<td>Biomedical Training</td>
</tr>
<tr>
<td>0715015</td>
<td>Autoimmunity</td>
<td>0503007</td>
<td>Computer-Assisted Instruction</td>
</tr>
<tr>
<td>10715020</td>
<td>Behavioral Medicine</td>
<td>0502009</td>
<td>Dental Health Education</td>
</tr>
<tr>
<td>0715025</td>
<td>Biofeedback</td>
<td>0502011</td>
<td>Drug Education</td>
</tr>
<tr>
<td>0715030</td>
<td>Birth/Congenital Defects</td>
<td>0502000</td>
<td>Educational/Instructional Programs</td>
</tr>
<tr>
<td>0715035</td>
<td>Cancer/Carcinogenesis</td>
<td>0507002</td>
<td>Emotionally Disturbed, Educ.</td>
</tr>
<tr>
<td>0715040</td>
<td>Cardiovascular Diseases</td>
<td>0507004</td>
<td>Handicapped, Education</td>
</tr>
<tr>
<td>0715045</td>
<td>Communicable Diseases</td>
<td>0502017</td>
<td>Health and Safety Education</td>
</tr>
<tr>
<td>0715050</td>
<td>Communicative Disorders, Hearing</td>
<td>0503016</td>
<td>Instructional Materials and Practices</td>
</tr>
<tr>
<td>0715055</td>
<td>Communicative Disorders, Speech</td>
<td>0503018</td>
<td>Learning Motivation</td>
</tr>
<tr>
<td>0715060</td>
<td>Convulsive Disorders</td>
<td>0507005</td>
<td>Learning Disabled, Education</td>
</tr>
<tr>
<td>0404007</td>
<td>Death and Dying</td>
<td>0502024</td>
<td>Medical Education</td>
</tr>
<tr>
<td>0715070</td>
<td>Death and Dying, Health and Physical Needs</td>
<td>0502027</td>
<td>Nursing Education</td>
</tr>
<tr>
<td>0715075</td>
<td>Diabetes</td>
<td>0502028</td>
<td>Nutrition Education</td>
</tr>
<tr>
<td>0715080</td>
<td>Diabetic Retinopathy</td>
<td>0502045</td>
<td>Pharmacy Education</td>
</tr>
<tr>
<td>0715085</td>
<td>Digestive Diseases and Disorders</td>
<td>0725000</td>
<td>ENVIRONMENT</td>
</tr>
<tr>
<td>0404009</td>
<td>Drugs/Drug Abuse</td>
<td>1007001</td>
<td>Biology, Environmental</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1007002</td>
<td>Chemistry, Environmental</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0725005</td>
<td>Environmental Health</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1007003</td>
<td>Environmental Effects</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0725010</td>
<td>Health and Safety Standards</td>
</tr>
</tbody>
</table>
Dyslexia 0715090
Emotional/Mental Health 0715095
Eye Diseases 0715100
Hyperplasia 0715105
Hypersensitivity 0715110
Hypertension 0715115
Immune System Disorders 0715120
Infectious Diseases/Agents 0715125
Mental Retardation 0715130
Metabolic Diseases 0715135
Neuromuscular Disorders 0715140
Obesity 0715145
Pain 0715150
Perinatal Disorders 0715155
Population Control 0413005
Pregnancy Disorders 0715160
Pulmonary Diseases 0715165
Rheumatic Diseases 0715170
Safety 0715175
Hospices 0730055
Nursing Homes 0730060
Patient Care and Education 0730065
Public Health 0730070
INSTRUMENTS/INSTRUMENTATION/ DEVICES
Automated Clinical Analysis 0735005
Computer-Assisted Design 1004002
Computer Graphics 1004004
Computer Modeling 1004005
Computer Storage & Retrieval 1004008
Electron Microscopy 1013038
Instrumentation, Medical 0735015
Instrumentation, Biological 1002024
Instrumentation, Scientific 1014001
Library Automation 1004020
Medical/Diagnostic Imaging 0706030
Microscopy 1013039
Pattern Recognition 1004022
Remote Sensing 1005020
Spectroscopy 1013034
Telemetry 0607023
Ultrasonic Technology 0607024
INTERVENTION, AGENTS FOR
Antibiotics 0740000
Anticonvulsants 0740005
Biological Response Modifiers 0740010
Chemotherapeutic Agents 0740015
Pharmaceuticals 0740020
Pharmaceuticals 0740025
Health, Radiation Effects 0715015
Occupational Health & Safety 0725020
Poison Control 0725025
Pollution, Air 1007005
Pollution, Water 1007008
Safety 0715175
HEALTH CARE
Child/Maternal Health 0730000
Family Health/Planning/Safety 0730005
Folk Medicine 0730010
Health Care Economics 0730015
Health Care Administration 0730020
Health Facilities Studies 0730025
Health Insurance 0730030
Health Maintenance Organizations 0730035
Health Manpower/Professions 0730040
Health Records 0730045
MATERIALS/PRODUCTS
Biomaterials 0750000
Blood/Blood Products/Transfusion 0750005
Contraceptives 0750020
Food Additives 0202001
Materials, Composite 1009007
Materials, Polymeric 1009008
Natural Products 0750025
METHODOLOGIES/PROCEDURES
Abortion (Induced) 0755000
Amniocentesis 0755005
Bioassay 0755010
Clinical Trial 0755015
Cloning of Cells 1002049
Cloning of Organisms 1002050
Disease Model 0755020
Drug Design 0755025
Etiology 0755030
Food Analysis 0202002
Gene Cloning 0755035
Genetic Manipulation 0755040
Nucleic Acid Sequencing 0755045
Population Studies 0413000
Preservation of Organs/Tissue 0755050
Psychometrics 0414013
Risk Factors/Analysis 0411005
Surveys and Survey Research 0404021
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0740030</td>
<td>Prosthetic Device, Hearing</td>
<td>0760000</td>
<td>MOLECULAR/CELLULAR ENTITIES</td>
</tr>
<tr>
<td>0740035</td>
<td>Prosthetic Device, Heart</td>
<td>0760005</td>
<td>Collagen</td>
</tr>
<tr>
<td>0740040</td>
<td>Prosthetic Device, Kidney</td>
<td>0760010</td>
<td>Endorphins</td>
</tr>
<tr>
<td>0740045</td>
<td>Prosthetic Device, Limbs</td>
<td>0760015</td>
<td>Gene Products</td>
</tr>
<tr>
<td>0740050</td>
<td>Prosthetic Device, Neural</td>
<td>0760020</td>
<td>Growth Factors</td>
</tr>
<tr>
<td>0740055</td>
<td>Prosthetic Device, Pancreas</td>
<td>0760025</td>
<td>Hormones</td>
</tr>
<tr>
<td>0740060</td>
<td>Prosthetic Device, Speech</td>
<td>0760030</td>
<td>Hybridomas</td>
</tr>
<tr>
<td>0740065</td>
<td>Prosthetic Device, Vision</td>
<td>0760035</td>
<td>Inhibitors</td>
</tr>
<tr>
<td>0740070</td>
<td>Prosthetic Devices (General)</td>
<td>0760040</td>
<td>Lipoproteins</td>
</tr>
<tr>
<td>0740075</td>
<td>Vaccine</td>
<td>0760045</td>
<td>Monoclonal Antibodies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0760050</td>
<td>Neurotransmitters</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0760055</td>
<td>Opiates</td>
</tr>
<tr>
<td>0745000</td>
<td>INTERVENTION, TYPES OF</td>
<td>0760060</td>
<td>Peptides</td>
</tr>
<tr>
<td>0745005</td>
<td>Chemotherapy</td>
<td>0760065</td>
<td>Prostaglandins</td>
</tr>
<tr>
<td>0745010</td>
<td>Dental Health and Hygiene</td>
<td>0760070</td>
<td>Proteins and Macromolecules</td>
</tr>
<tr>
<td>0745015</td>
<td>Detoxification</td>
<td>0760075</td>
<td>Receptors</td>
</tr>
<tr>
<td>0745020</td>
<td>Diagnosis, Medical</td>
<td></td>
<td>Recombinant DNA</td>
</tr>
<tr>
<td>0745025</td>
<td>Dialysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0745030</td>
<td>Exercise</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0745035</td>
<td>Health Promotion</td>
<td>0765000</td>
<td>NATURAL PROCESSES</td>
</tr>
<tr>
<td>0745040</td>
<td>Immunosuppression</td>
<td>1002048</td>
<td>Biodegradation</td>
</tr>
<tr>
<td>0745045</td>
<td>Immunotherapy</td>
<td>0765005</td>
<td>Bioenergetics</td>
</tr>
<tr>
<td>0745050</td>
<td>Preventive Dentistry</td>
<td>0765010</td>
<td>Biosynthesis</td>
</tr>
<tr>
<td>0745055</td>
<td>Preventive Medicine</td>
<td>0765015</td>
<td>Gene Regulation</td>
</tr>
<tr>
<td>0745060</td>
<td>Psychotherapy</td>
<td>0765020</td>
<td>Metabolism</td>
</tr>
<tr>
<td>0415000</td>
<td>Therapy/Rehabilitation</td>
<td>0765025</td>
<td>Metabolism, Lipid</td>
</tr>
<tr>
<td>0745065</td>
<td>Transplantation of Organs</td>
<td>0765030</td>
<td>Metabolism, Mineral</td>
</tr>
<tr>
<td>0765035</td>
<td>Pathophysiology</td>
<td>0785030</td>
<td>Chiropractic</td>
</tr>
<tr>
<td>1002042</td>
<td>Reproduction</td>
<td>0785035</td>
<td>Clinical Medicine, General</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0785040</td>
<td>Dentistry</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0785045</td>
<td>Dermatology</td>
</tr>
<tr>
<td>0770000</td>
<td>PATIENT/VOLUNTEER CLASSIFICATION</td>
<td>0785050</td>
<td>Endocrinology</td>
</tr>
<tr>
<td>0403001</td>
<td>Adolescents</td>
<td>0785055</td>
<td>Epidemiology</td>
</tr>
<tr>
<td>0403019</td>
<td>Adults</td>
<td>0785060</td>
<td>Gastroenterology</td>
</tr>
<tr>
<td>0770005</td>
<td>Children (Patients)</td>
<td>0785065</td>
<td>Health, Allied Fields</td>
</tr>
<tr>
<td>0770010</td>
<td>Handicapped/Disabled</td>
<td>0785070</td>
<td>Hematology</td>
</tr>
<tr>
<td>0770015</td>
<td>Hospitalized Patient</td>
<td>0785075</td>
<td>Medical Genetics</td>
</tr>
<tr>
<td>0403020</td>
<td>Infants</td>
<td>0785080</td>
<td>Medicine, Family Practice</td>
</tr>
<tr>
<td>0775000</td>
<td>PHYSIOLOGICAL/DEVELOPMENT PROCESS</td>
<td>0785085</td>
<td>Medicine, Internal</td>
</tr>
<tr>
<td>0404004</td>
<td>Child Psychology/Development</td>
<td>0785090</td>
<td>Midwifery</td>
</tr>
<tr>
<td>0414005</td>
<td>Cognitive Development/Processes</td>
<td>0785095</td>
<td>Nephrology</td>
</tr>
<tr>
<td>0775005</td>
<td>Hearing</td>
<td>0785100</td>
<td>Neuroanatomy</td>
</tr>
<tr>
<td>0413002</td>
<td>Human Reproduction/Fertility</td>
<td>0785105</td>
<td>Neuroendocrinology</td>
</tr>
<tr>
<td>0775010</td>
<td>Lactation</td>
<td>0785110</td>
<td>Neurology</td>
</tr>
<tr>
<td>0410001</td>
<td>Language Acquisition/Development</td>
<td>0785115</td>
<td>Neuropharmacology</td>
</tr>
<tr>
<td>1002059</td>
<td>Morphogenesis</td>
<td>0785120</td>
<td>Neurosurgery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0785125</td>
<td>Nurse Practitioner</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0785130</td>
<td>Nursing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0785135</td>
<td>Obstetrics-Gynecology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0785140</td>
<td>Oncology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0785145</td>
<td>Ophthalmology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0785150</td>
<td>Optometry</td>
</tr>
<tr>
<td>Code</td>
<td>Topic</td>
<td>Code</td>
<td>Topic</td>
</tr>
<tr>
<td>---------</td>
<td>------------------------------------------</td>
<td>---------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>0775015</td>
<td>Physical Growth/Retardation</td>
<td>0785155</td>
<td>Orthopedics</td>
</tr>
<tr>
<td>1002034</td>
<td>Physiological Processes</td>
<td>0785160</td>
<td>Otorhinolaryngology</td>
</tr>
<tr>
<td>0775020</td>
<td>Pregnancy</td>
<td>0785165</td>
<td>Pathology</td>
</tr>
<tr>
<td>0775025</td>
<td>Prenatal Factors</td>
<td>0785170</td>
<td>Pediatrics</td>
</tr>
<tr>
<td>0775030</td>
<td>Teratology</td>
<td>0785175</td>
<td>Periodontics</td>
</tr>
<tr>
<td>1002044</td>
<td>Vertebrate Physiology</td>
<td>0785180</td>
<td>Physical Medicine and Rehabilitation</td>
</tr>
<tr>
<td>1002046</td>
<td>Vision</td>
<td>0785185</td>
<td>Psychiatry</td>
</tr>
<tr>
<td>0780000</td>
<td>RESEARCH RESOURCES</td>
<td>0785190</td>
<td>Radiology</td>
</tr>
<tr>
<td>1002002</td>
<td>Animal Breeding and Facilities</td>
<td>0785195</td>
<td>Rheumatology</td>
</tr>
<tr>
<td>0780005</td>
<td>Biologials Resources</td>
<td>0785200</td>
<td>Serology</td>
</tr>
<tr>
<td>0780010</td>
<td>Biomedical Research Resources, Other</td>
<td>0785205</td>
<td>Sports Medicine</td>
</tr>
<tr>
<td>0780015</td>
<td>Cell Lines</td>
<td>0785210</td>
<td>Surgery</td>
</tr>
<tr>
<td>1103002</td>
<td>Research Libraries</td>
<td>0785215</td>
<td>Tropical Medicine</td>
</tr>
<tr>
<td>0780020</td>
<td>Tissue Culture</td>
<td>0785220</td>
<td>Urology</td>
</tr>
<tr>
<td>1014002</td>
<td>SCIENCE PLANNING/POLICY</td>
<td>0201058</td>
<td>Veterinary Medicine</td>
</tr>
<tr>
<td>0201011</td>
<td>Animal Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1014003</td>
<td>Animal Research Policy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0783015</td>
<td>Health Planning/Policy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0783005</td>
<td>Human Subjects Policy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0783010</td>
<td>Ethics, Medical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0785000</td>
<td>SPECIALTIES OF MEDICAL AND ALLIED FIELDS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0785005</td>
<td>Aerospace Biomedicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0785010</td>
<td>Allergy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0785015</td>
<td>Anesthesiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0785020</td>
<td>Audiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0785025</td>
<td>Cardiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1016002</td>
<td>Technology Assessment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1016003</td>
<td>Technology Planning/Policy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1016004</td>
<td>Technology Transfer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0795005</td>
<td>Therapy Evaluation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>